The Role of Varenicline in Treating Opioid Dependence: A Pilot Study
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Mayo Clinic
- 入组人数
- 21
- 试验地点
- 1
- 主要终点
- assessment of opioid withdrawal symptoms
研究概览
简要总结
The objective of this proposal is to explore the potential of varenicline as a pharmacotherapeutic agent for opioid dependence and addiction.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Varenicline
We will be comparing Varenicline to placebo in a single-blinded placebo controlled, randomized study
干预措施: Varenicline (Drug)
Placebo
We will be using a placebo in a randomized, controlled, single-blinded trial to look at varenicline for the indication of facilitating opioid tapering in opioid-dependent patients with chronic pain.
干预措施: Placebo (Drug)
结局指标
主要结局
assessment of opioid withdrawal symptoms
时间窗: 45 days
During their treatment, patients are closely monitored by a multidisciplinary team, and there are regular assessments of pain, depression, substance use, and pain-related physical and emotional functioning
Assessment of cravings at one month following opioid tapering
时间窗: 45 days
During their treatment, patients are closely monitored by a multidisciplinary team, and there are regular assessments of pain, depression, substance use, and pain-related physical and emotional functioning
次要结局
未报告次要终点